EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JUL 2022
TABLES
147
PAGES
379
EDITION
10
PRICE
USD 4950
CODE
MCP13362
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global microRNA (miRNA) Market to Reach $485.3 Million by 2026
miRNAs or microRNAs, non-coding short RNA molecules regulate gene expression by attaching to target mRNAs, leading to gene silencing and translational repression. Commonly found among plants, animals, and certain viruses, microRNAs or miRNAs are RNA molecules that have a critical role in regulating gene expression as well as RNA silencing. Key drivers propelling growth in the global microRNA market include greater awareness, increasing emphasis on R&D activities, growth of advanced and well-organized technology, rising government initiatives globally, escalating government investments in healthcare, along with advances in genomic technologies and molecular biology. The growth of microRNA in oncology can be attributed to the growing burden of cancer as well as other cardiovascular diseases, broader therapeutic applications, lowering the cost of sequencing, and greater acceptance of the technology. Rising microRNA adoption in emerging countries such as India, China, among others will offer new growth opportunities. The growing use of microRNA biomarkers is augmenting growth in the market. Such biomarkers play a particularly important role in data-driven approaches, genome-wide population-based studies because they show high reproducibility and robustness in comparison to conventional procedures. Furthermore, the growing relevance of liquid biopsies is further driving its popularity in the discovery and development of biomarkers. However, intensified demand for highly skilled personnel and challenges regarding in-house development are major hurdles to growth in the global market.
Amid the COVID-19 crisis, the global market for microRNA (miRNA) estimated at US$282.6 Million in the year 2022, is projected to reach a revised size of US$485.3 Million by 2026, growing at a CAGR of 13.8% over the analysis period. Products, one of the segments analyzed in the report, is projected to record 12.2% CAGR and reach US$290.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 15.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $120.5 Million in 2022, While China is Forecast to Reach $50.7 Million by 2026
The microRNA (miRNA) market in the U.S. is estimated at US$120.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$50.7 Million by the year 2026 trailing a CAGR of 17.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR. The North American region dominates the global market, owing to technological advances, government support, and excellent medical reimbursement facilities. Ever-increasing clinical trials seeking to develop novel diagnostics and therapeutics, particularly in the US, is another key growth driver. Growth in the Europe market is because of increased funding towards research in countries like Germany to encourage the entry of startups in the molecular diagnostics industry, particularly in microRNA. The microRNA market in Asia Pacific is likely to gain considerable momentum due to increasing consumer awareness, rapid growth in population, supportive government policies, healthcare infrastructure modernization, and escalating foreign investments in developing nations like India and China in the regional market. The Asia Pacific region will also be driven by advances in proteomics and genomics along with increasing adoption of novel tools that help meet research goals.
SELECT PLAYERS
Abcam Plc; Agilent Technologies, Inc.; Biodynamics Laboratory Inc.; BioGenex; Bio-Rad Laboratories Inc.; BioVendor — Laboratorní medicína a.s.; Dharmacon, a Horizon Discovery Group Co.; F. Hoffmann-La Roche Ltd; GeneCopoeia, Inc.; HTG Molecular Diagnostics, Inc.; Lexogen GmbH; Meridian Bioscience; Miltenyi Biotec; NanoString Technologies, Inc.; New England Biolabs; Norgen Biotek Corp; OriGene Technologies, Inc.; Promega Corporation; QIAGEN NV; Quantabio; SeqMatic LLC; Sistemic Scotland Limited; System Biosciences LLC; Takara Bio Inc.; Thermo Fisher Scientific, Inc.; TriLink BioTechnologies Inc.
SEGMENTS
» Type (Products, Services) » Application (Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases, Other Applications) » End-Use (Academic & Government Research Institutes, Biotech & Pharma Companies, Other End-Uses)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
microRNA (miRNA) – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
A Prelude to MicroRNA |
Impact of Covid-19 and a Looming Global Recession |
2020 Marked as a Year of Disruption & Transformation |
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021 |
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 |
COVID-19 Impact on mRNA Market |
Global Market Prospects and Outlook |
Global miRNA Market Set to Witness Rapid Growth |
Disease Diagnostics Segment Leads the Market |
MicroRNAs Likely to Be Instrumental in Disease Diagnosis and Treatment |
Polymerase Chain Reaction (PCR) Dominates the Instruments Category |
Academic and Government Research Institutes Holds the Largest Share |
North America Dominates Global miRNA Market, Asia-Pacific to Witness Steady Growth |
Competition |
Increasing Emphasis on R&D by Players to Boost Market Growth |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead |
EXHIBIT: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others |
Increasing Application in Cancer Diagnostics as Biomarkers to Drive Market Growth |
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
EXHIBIT 4: Breakdown of Total Number of Cancer Cases by Region: 2020 |
EXHIBIT: Breakdown of Total Number of Cancer Cases by Type: 2020 |
The Future of miRNA-based Cancer Biomarkers |
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth |
EXHIBIT 5: Global Number of Deaths Caused Due to Communicable Diseases (In 000s) |
EXHIBIT: Infection Rates of Viruses ((per infected person)) Involved in Outbreaks Worldwide: 2020 |
EXHIBIT 10: Infectious Diseases Related Mortality High Among Children below 5 Years: Breakdown of Leading Causes of Death in Children below 5 Years (in %) |
MicroRNA Biomarkers Hold Promise for Diagnosis of Infectious Diseases |
Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth |
Increasing Investments in miRNA to Bolster Market Growth |
Diagnostics and Therapeutics Investments |
Standard Methods Utilized to measure miRNA Biomarkers |
Advancements in Detection Methodologies Focus on Enhancing Sensitivity and Selectivity of miRNA Detection |
Increasing Demand for Liquid Biopsies to Drive the MicroRNA Market |
miRNA by Type of Gastrointestinal Cancers |
Circulating miRNAs as Cancer Detectors |
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market |
EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 |
Growing Global Healthcare Spending and Supportive Government Initiatives Boost Market Prospects |
EXHIBIT 6: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 |
EXHIBIT 9: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018 |
miRNA and Next Generation Sequencing |
Market Restraints |
AN INSIGHT INTO MIRNA APPLICATIONS |
CANCER |
Role of miRNA in Cancer Cell |
HEART DISEASE |
miRNA-712 |
Human Homolog—microRNA-205 |
KIDNEY DISEASE |
NERVOUS SYSTEM |
Stroke |
ALCOHOLISM |
OBESITY |
HEMOSTASIS |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
World 11-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
USA 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
USA 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
USA 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Canada 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Canada 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Canada 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
JAPAN |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Japan 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Japan 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Japan 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
CHINA |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
China 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
China Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
China 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
China Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
China 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
EUROPE |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Europe 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
FRANCE |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
France 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
France Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
France 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
France Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
France 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
GERMANY |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Germany 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Germany 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Germany 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Italy 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Italy 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Italy 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
UNITED KINGDOM |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
UK 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
UK 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
UK 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
ASIA-PACIFIC |
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Asia-Pacific 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of World 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of World 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR |
Rest of World 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 64 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com